Wednesday, October 14, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 12, 2026

Retiring with $1.2 Million? Here's How to Avoid Running Out of Savings

View original at nasdaq.com
Retiring with $1.2 Million? Here's How to Avoid Running Out of Savings Key Points Even though $1.2 million is a nice amount of money, it needs to be managed carefully…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • People born in 1960 or later can collect full monthly Social Security benefits at age 67.

    60% confidence
  • For each year a claim is delayed past full retirement age until age 70, Social Security benefits get a permanent 8% boost.

    60% confidence
  • More conservative investors, or those retiring in their 50s, may need to stick to a 3% or 3.5% withdrawal rate; those retiring later may be able to take larger percentage withdrawals.

    60% confidence
  • For a fairly equal mix of stocks and bonds and a 20- to 30-year retirement, the 4% withdrawal rule might work.

    60% confidence
  • Keeping one to three years' worth of planned expenses in cash allows retirees to leave investments untouched during downturns and cover unplanned expenses.

    60% confidence
  • A little-known Social Security claiming strategy could pay retirees as much as $23,760 more per year.

    60% confidence
  • The Motley Fool cannot and does not provide personalized investing or financial advice; the information is for informational and educational purposes only.

    60% confidence

Data points we hold from this source

Social Security Administration · maximum claiming strategy bonus23760 USD
Social Security Administration · full retirement age67 years
Social Security Administration · recommended safe withdrawal rate4 percent
Social Security Administration · delayed retirement credit rate8 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com